Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
出版年份 2018 全文链接
标题
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
作者
关键词
-
出版物
mSphere
Volume 3, Issue 4, Pages -
出版商
American Society for Microbiology
发表日期
2018-08-20
DOI
10.1128/mspheredirect.00378-18
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)
- (2016) Betty Lam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
- (2016) Noelia Purroy et al. Oncotarget
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma
- (2015) Hirofumi Bekki et al. BMC CANCER
- Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer
- (2015) Bojiang Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia
- (2015) Romain Gioia et al. JOURNAL OF PATHOLOGY
- Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age
- (2015) Ting-Xun Lu et al. Scientific Reports
- A Computational Study of the Effects of Syk Activity on B Cell Receptor Signaling Dynamics
- (2015) Reginald McGee et al. Processes
- Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
- (2015) Chong-kui Sun et al. Oncotarget
- Syk-Induced Phosphatidylinositol-3-Kinase Activation in Epstein-Barr Virus Posttransplant Lymphoproliferative Disorder
- (2013) O. Hatton et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
- (2013) J. A. Kanakry et al. BLOOD
- Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma
- (2013) K. Fish et al. BLOOD
- EBV-Related Lymphomas: New Approaches to Treatment
- (2013) Jennifer A. Kanakry et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
- (2013) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A
- (2012) Jamie L. Dargart et al. ANTIVIRAL RESEARCH
- Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal
- (2012) Niklas Engels et al. Cell Communication and Signaling
- Epstein-Barr Virus Latent Membrane Protein-2A Induces ITAM/Syk- and Akt-Dependent Epithelial Migration through V-Integrin Membrane Translocation
- (2012) J. A. Fotheringham et al. JOURNAL OF VIROLOGY
- Epstein–Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1
- (2012) Joo Hyun Kim et al. LEUKEMIA & LYMPHOMA
- Immunotherapy for EBV-associated malignancies
- (2011) Anna Merlo et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
- (2011) Ralf Trappe et al. LANCET ONCOLOGY
- Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis
- (2011) S Fruchon et al. LEUKEMIA
- Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus-Related Burkitt's Lymphoma
- (2011) O. Cen et al. MOLECULAR CANCER THERAPEUTICS
- Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
- (2010) Hans-Peter Gerber BIOCHEMICAL PHARMACOLOGY
- Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth
- (2010) Jiyuan Ke et al. Molecular Cancer
- Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
- (2009) J. I. Cohen et al. ANNALS OF ONCOLOGY
- Syk and pTyr'd: Signaling through the B cell antigen receptor
- (2009) Robert L. Geahlen BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Expression of EBV Latent Antigens, Mammalian Target of Rapamycin, and Tumor Suppression Genes in EBV-Positive Smooth Muscle Tumors: Clinical and Therapeutic Implications
- (2009) K. W. Ong et al. CLINICAL CANCER RESEARCH
- Epstein–Barr virus LMP2A accelerates MYC-induced lymphomagenesis
- (2009) R Bultema et al. ONCOGENE
- Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis
- (2009) K. T. Bieging et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunotherapy targeting EBV-expressing lymphoproliferative diseases
- (2008) Catherine M. Bollard et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway
- (2008) L. J. Anderson et al. JOURNAL OF GENERAL VIROLOGY
- Current understanding of the role of Epstein–Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas
- (2008) Jeffrey I. Cohen et al. LEUKEMIA & LYMPHOMA
- The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling
- (2008) Masato Ikeda et al. VIROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation